{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:34Z","timestamp":1792831054593,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110560","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:44:55Z","timestamp":1790379895000},"page":"110560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rationale design and synthesis of new quinazoline derivatives as DNA intercalators and topoisomerase II inhibitors"],"prefix":"10.1016","volume":"183","author":[{"given":"Amr","family":"Helmy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamdouh F.A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim H.","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem A.","family":"Mahdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10512","key":"10.1016\/j.bioorg.2026.110560_bb0005","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(25)01570-3","article-title":"Global cancer burden: progress, projections, and challenges","volume":"406","author":"Luo","year":"2025","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110560_bb0010","first-page":"4714","article-title":"Macrophages and metastasis\u2014a biological approach to cancer therapy: presidential address","volume":"45","author":"Fidler","year":"1985","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110560_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110560_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118679","article-title":"Design and synthesis of pyrazolopyrimidinone derivatives as dual VEGFR\/Aurora kinase inhibitors against hepatocellular and breast carcinomas","volume":"192","author":"Anwer","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0025","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110560_bb0030","author":"WHO"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110560_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrc749","article-title":"DNA and its associated processes as targets for cancer therapy","volume":"2","author":"Hurley","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110560_bb0040","series-title":"Medicinal Chemistry of Anticancer Drugs, Chapter 7","first-page":"200","author":"Avendano","year":"2008"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110560_bb0045","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.bmcl.2007.12.035","article-title":"Novel 3-alkoxy-1H-pyrazolo [3, 4-d] pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors","volume":"18","author":"Ducray","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110560_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejmech.2017.02.044","article-title":"Diphenylurea derivatives for combating methicillin-and vancomycin-resistant Staphylococcus aureus","volume":"130","author":"Eissa","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","article-title":"Mitoxantrone: a new anticancer drug with significant clinical activity","volume":"105","author":"Shenkenberg","year":"1986","journal-title":"Ann. Intern. Med."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110560_bb0065","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/jm801331y","article-title":"The p K BHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists","volume":"52","author":"Laurence","year":"2009","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110560_bb0070","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/cbdd.14116","article-title":"DNA intercalators as anticancer agents","volume":"100","author":"Venugopal","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110560_bb0080","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1021\/acs.jmedchem.6b00065","article-title":"Rapid discovery and structure\u2013activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase","volume":"59","author":"Fraser","year":"2016","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110560_bb0085","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110560_bb0090","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jhet.56","article-title":"Synthesis of 2, 3-dichloroquinoxalines via Vilsmeier reagent chlorination","volume":"46","author":"Romer","year":"2009","journal-title":"J. Heterocyclic Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110560_bb0095","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110560_bb0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1023\/A:1008018106064","article-title":"Structure\u2013affinity relationships for the binding of actinomycin D to DNA","volume":"11","author":"Gallego","year":"1997","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"38","key":"10.1016\/j.bioorg.2026.110560_bb0105","doi-asserted-by":"crossref","first-page":"11493","DOI":"10.1021\/bi00204a011","article-title":"Binding of actinomycin D to the T (G) nT motif of double-stranded DNA: determination of the guanine requirement in nonclassical, non-GpC binding sites","volume":"33","author":"Bailey","year":"1994","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110560_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000237","article-title":"Design and discovery of new 1, 2, 4-triazolo [4, 3-c] quinazolines as potential DNA intercalators and topoisomerase II inhibitors","volume":"354","author":"Alesawy","year":"2021","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110560_bb0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejmech.2011.10.057","article-title":"Disubstituted quinazoline derivatives as a new type of highly selective ligands for telomeric G-quadruplex DNA","volume":"47","author":"Li","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110560_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2013.01.051","article-title":"New quinazoline derivatives for telomeric G-quadruplex DNA: effects of an added phenyl group on quadruplex binding ability","volume":"63","author":"He","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110560_bb0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmech.2015.12.032","article-title":"Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors","volume":"109","author":"Zhang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110560_bb0130","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.bmcl.2017.06.071","article-title":"Discovery of dual Axl\/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy","volume":"27","author":"Goff","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110560_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115872","article-title":"Design, synthesis, and anti-proliferative evaluation of new quinazolin-4 (3H)-ones as potential VEGFR-2 inhibitors","volume":"29","author":"El-Adl","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110560_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21608\/ajps.2021.187748","article-title":"Review on the significance of QUINAZOLINE derivatives as broad spectrum anti-CANCER agents","volume":"64","author":"El-Zahabi","year":"2021","journal-title":"Al-Azhar J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.110560_bb0145","doi-asserted-by":"crossref","first-page":"109608","DOI":"10.1016\/j.bioorg.2026.109608","article-title":"Synthesis of 4-chloro-N\u2032-(2-cyanoacetyl) benzohydrazide derivatives, cytotoxicity, VEGFR-2\/EGFRT790M bioassays and in silico docking\/ADMET studies","volume":"172","author":"Deghaidi","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110560_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108746","article-title":"ADMET, docking, anticancer evaluations, design and synthesis of pyrazolo [1, 5-a] pyrimidines substituted with furan and phenyldiazene as dual EGFRT790M and VEGFR-2 inhibitors","volume":"163","author":"Alsulaimany","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110560_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejmech.2013.11.029","article-title":"Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling","volume":"74","author":"Rescifina","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110560_bb0160","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bmc.2010.12.037","article-title":"Benzoquinazoline derivatives as new agents affecting DNA processing","volume":"19","author":"Marzaro","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110560_bb0165","doi-asserted-by":"crossref","first-page":"11458","DOI":"10.1039\/D5RA08997B","article-title":"Pyrazole\/pyrimidine derivatives endowed with azobenzenes as dual EGFRT790M and VEGFR-2 inhibitors: anticancer, docking, synthesis, design and ADMET assessments","volume":"16","author":"Anwer","year":"2026","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbrc.2010.11.110","article-title":"Determining the binding mode and binding affinity constant of tyrosine kinase inhibitor PD153035 to DNA using optical tweezers","volume":"404","author":"Cheng","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7\u20138","key":"10.1016\/j.bioorg.2026.110560_bb0175","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.fitote.2008.06.007","article-title":"Cytotoxic activity screening of some indigenous Thai plants","volume":"79","author":"Prayong","year":"2008","journal-title":"Fitoterapia"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10408360500295626","article-title":"BCL2 family of apoptosis-related genes: functions and clinical implications in cancer","volume":"43","author":"Thomadaki","year":"2006","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110560_bb0185","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tcb.2008.01.007","article-title":"How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?","volume":"18","author":"Chipuk","year":"2008","journal-title":"Trends Cell Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110560_bb0190","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s11030-017-9776-1","article-title":"Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents","volume":"21","author":"El-Naggar","year":"2017","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.110560_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103422","article-title":"Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers","volume":"94","author":"Mahdy","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110560_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107437","article-title":"Novel quinazolin-2-yl 1, 2, 3-triazole hybrids as promising multi-target anticancer agents: design, synthesis, and molecular docking study","volume":"148","author":"El Hamaky","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"2B","key":"10.1016\/j.bioorg.2026.110560_bb0205","first-page":"582","article-title":"Synthesis, characterization and evaluation antimicrobial activity of some new substituted 2-mercapto-3-phenyl-4 (3H)-quinazolinone","volume":"55","author":"Al-Khuzaie","year":"2014","journal-title":"Iraqi J. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0210","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1080\/14756366.2022.2118735","article-title":"Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity","volume":"37","author":"Sonousi","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110560_bb0215","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1039\/C7MD00171A","article-title":"Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells","volume":"8","author":"Kumari","year":"2017","journal-title":"Medchemcomm"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0220","article-title":"Design, synthesis and pharmacological screening of 2-(2-(benzo [d] oxazol-2-yl) phenylamino)-n-(substituted phenyl) acetamides as anti-inflammatory and analgesic agents","volume":"5","author":"Gautam","year":"2014","journal-title":"J. Adv. Sci. Res."},{"key":"10.1016\/j.bioorg.2026.110560_bb0225","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ejmech.2015.02.026","article-title":"Discovery of novel AHLs as potent antiproliferative agents","volume":"93","author":"Ren","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110560_bb0230","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00044-019-02434-1","article-title":"Synthesis, structural characterization, and cytotoxic evaluation of chalcone derivatives","volume":"28","author":"Bandeira","year":"2019","journal-title":"Med. Chem. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110560_bb0235","doi-asserted-by":"crossref","first-page":"21781","DOI":"10.1038\/s41598-021-01292-5","article-title":"New chalcone derivatives as potential antimicrobial and antioxidant agent","volume":"11","author":"Okolo","year":"2021","journal-title":"Sci. Rep."},{"issue":"52","key":"10.1016\/j.bioorg.2026.110560_bb0240","doi-asserted-by":"crossref","first-page":"33525","DOI":"10.1039\/D2RA06188K","article-title":"Design, synthesis, and biological evaluation of novel bioactive thalidomide analogs as anticancer immunomodulatory agents","volume":"12","author":"Kotb","year":"2022","journal-title":"RSC Adv."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110560_bb0245","doi-asserted-by":"crossref","first-page":"10488","DOI":"10.1039\/D3RA00066D","article-title":"Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents","volume":"13","author":"Kotb","year":"2023","journal-title":"RSC Adv."},{"issue":"112","key":"10.1016\/j.bioorg.2026.110560_bb0250","doi-asserted-by":"crossref","first-page":"92596","DOI":"10.1039\/C5RA16741H","article-title":"Targeted delivery of a novel peptide\u2013docetaxel conjugate to MCF-7 cells through neuropilin-1 receptor: reduced toxicity and enhanced efficacy of docetaxel","volume":"5","author":"Saha","year":"2015","journal-title":"RSC Adv."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2026.110560_bb0255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.110560_bb0260","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bioorg.2018.10.058","article-title":"Novel nalidixic acid derivatives targeting topoisomerase II enzyme; design, synthesis, anticancer activity and effect on cell cycle profile","volume":"83","author":"Khalil","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110560_bb0265","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/np50089a004","article-title":"A colorimetric microassay for the detection of agents that interact with DNA","volume":"55","author":"Burres","year":"1992","journal-title":"J. Nat. Prod."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110560_bb0270","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1080\/17568919.2024.2421150","article-title":"Design and synthesis of new nicotinamides as immunomodulatory VEGFR-2 inhibitors and apoptosis inducers","volume":"16","author":"Yousef","year":"2024","journal-title":"Future Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110560_bb0275","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1080\/07391102.2023.2294170","article-title":"New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis, in vitro, and in silico studies","volume":"43","author":"Yousef","year":"2025","journal-title":"J. Biomol. Struct. Dyn."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:02:16Z","timestamp":1792828936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"alternative-id":["S0045206826010965"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110560","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale design and synthesis of new quinazoline derivatives as DNA intercalators and topoisomerase II inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110560"}}